Reinforcement learning and hit expansion identify SARS-CoV-2 Mpro inhibitor series
A mixed workflow using deep reinforcement learning, pharmacophore and shape filters, docking and hit expansion reports three SARS-CoV-2 main-protease inhibitor series with biochemical IC50 values of 1.3–2.3 μM. The paper combines generated and commercially sourced hits; not every final inhibitor is claimed as directly model-generated. PDB entry 8R11 was released before the article and already disclosed a bound compound structure, so no priority claim is made for that structure. These biochemical findings do not establish antiviral efficacy or clinical safety.
Technology: Deep reinforcement learning; pharmacophore/shape filtering; docking
Publication: Peer-reviewed paper · Test context: direct test. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: direct test
- Tested: Publisher abstract reports three experimentally validated Mpro inhibitor series with IC50 1.3–2.3 μM; PDB 8R11 pre-dates the paper.
- Still unknown: Exact assignment of each final inhibitor to generated versus commercially sourced material and prior chemotype overlap not fully audited; no antiviral or clinical claims.
- AI role: Reinforcement learning generates candidate structures; computational filters and hit expansion guide follow-up, but commercially sourced hits also contributed.
Evidence sources: https://pubs.rsc.org/en/content/articlepdf/2024/md/d4md00106k
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: linked separately.
Review date: 16 Nov 2026. Review scope: Primary RSC article landing page and full-text PDF abstract; first-publication date verified. PDB identity/release was reported in input ledger and should be retained as earlier structure disclosure..
Editorial assessment: Impact 3/5 · Validation 3/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.